Please Wait
Applying Filters...
menu
    • menu
    TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

    Virtual Booth

    Contact Supplier

    Your reliable CDMO partner - agile, scalable, top-quality Small Molecule API & HPAPI solutions from concept to market

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    An Enquiry

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Ruzasvir

    DEVELOPMENTS

    INTERMEDIATES

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Atea Reports Data For Bemnifosbuvir + Ruzasvir At Liver Meeting
    Atea Reports Data For Bemnifosbuvir + Ruzasvir At Liver Meeting

    07 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/07/3183594/0/en/Atea-Pharmaceuticals-Presents-New-Data-Supporting-the-Fixed-Dose-Combination-of-Bemnifosbuvir-and-Ruzasvir-as-a-Potential-Best-in-Class-Regimen-for-Treatment-of-Hepatitis-C-Virus-I.html

    GLOBENEWSWIRE
    07 Nov 2025
    Share Share
    Atea To Present Bemnifosbuvir + Ruzasvir Data For Hepatitis C
    Atea To Present Bemnifosbuvir + Ruzasvir Data For Hepatitis C

    07 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/07/3162443/0/en/Atea-Pharmaceuticals-to-Present-New-Data-Supporting-Combination-of-Bemnifosbuvir-and-Ruzasvir-as-Potential-Best-in-Class-Regimen-for-Treatment-of-Hepatitis-C-Virus-Infection-at-The.html

    GLOBENEWSWIRE
    07 Oct 2025
    Share Share
    Atea Presents Full Phase 2 Data on Hep C Combo at EASL 2025
    Atea Presents Full Phase 2 Data on Hep C Combo at EASL 2025

    07 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/07/3075940/0/en/Atea-Pharmaceuticals-Announces-Full-Results-from-Phase-2-Study-of-Regimen-of-Bemnifosbuvir-and-Ruzasvir-for-Treatment-of-Hepatitis-C-Virus-HCV-Presented-at-EASL-Congress-2025.html

    GLOBENEWSWIRE
    07 May 2025
    Share Share
    Atea Pharmaceuticals to Present Best-in-Class Hepatitis C Regimen
    Atea Pharmaceuticals to Present Best-in-Class Hepatitis C Regimen

    23 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/23/3066217/0/en/Atea-Pharmaceuticals-to-Present-New-Data-Showcasing-Potential-Best-in-Class-Regimen-of-Bemnifosbuvir-and-Ruzasvir-for-Treatment-of-Hepatitis-C-Virus-at-EASL-Congress-2025.html

    GLOBENEWSWIRE
    23 Apr 2025
    Share Share
    Atea Pharmaceuticals Starts Phase 3 Study on Hepatitis C Virus
    Atea Pharmaceuticals Starts Phase 3 Study on Hepatitis C Virus

    09 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/09/3058258/0/en/Atea-Pharmaceuticals-Announces-Dosing-of-First-Patient-in-C-BEYOND-Phase-3-Study-Evaluating-Regimen-of-Bemnifosbuvir-and-Ruzasvir-for-Treatment-of-Hepatitis-C-Virus.html

    GLOBENEWSWIRE
    09 Apr 2025
    Share Share
    Atea Pharma Announces Positive Ph 2 Results for HCV Regimen
    Atea Pharma Announces Positive Ph 2 Results for HCV Regimen

    04 Dec 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/12/04/2991333/0/en/Atea-Pharmaceuticals-Announces-Positive-Results-from-Phase-2-Study-of-Bemnifosbuvir-and-Ruzasvir-Regimen-for-Treatment-of-Hepatitis-C-Virus-HCV.html

    GLOBENEWSWIRE
    04 Dec 2024
    Share Share